[Letter to Daniel K. Inouye from the Intramural Members of NIH/FDA gp160 Advisory Panel]

SENT BY: XEROX Telecopie 7017; 9-30-93; 9:04; 2129515381-h 4153910513;
SENT hy:'AMFAR-DG;0 24-93 2 57P;212777813O 2
POSXI'ON STATEMENT OF AtFAR ON E $3+4o ML ION
DOD AmPOPRIATION JOR A T5AEIC
DV VACCINZTIAL
11 The American Foundation for AIDS ieseaz'ch (AmFAR) grjws with the ccwnsen~sus of
an NIH panel which met last summer that any olmna al t VWofglIV vaccine prodct5
s potetilal themp rnlc agents In HIV inroAon to conducted only in the etting of a
controlled, jI- st#y. (iven the very limit d offlacy of the single qucit,
Mic S ys 1p60, prvpoed to be bested, AniFAR does not e the nead for a
tuie j I $flL trial At thiS time.
2. AmPAR recognizs that a multi-vaccine ril coul~d not be con4diote4 with UheS20
million alloc $lon Th NIH has stated that no RddlI lon~1 funds wcie avlleble to
supportIa expanded tnal at this time.
3. AmiPAR belive that, In th. best interests of both clcal and basic AIDS rmamrch,
the $20 million a olation should be used by the DOD to fund peeerzisvlewed
extramural AIDS tr serch gms. AmFAR bass this belil on the very limited
clncland test'tubc data available on the mechanismi of acton, not only of gpl6O,
but of other l{IV womponens propose to be ued in a similar fahoc, inluding but
not limited to gpl12O, gp41 uaid p 17. These new funds could be beat used in axploring
thea immuunologic and viroloaje effects of such potential thatap.lt~c Vi4cIe producti
in various exprimnsntal models, avuiiih the prcmatwu8 initiation of singlecenut
tr5.